Predictors of transplant rejection determined by peripheral blood gene-expression profiling
View Patent ↗The present invention provides methods and kits for predicting transplant rejection or tolerance. Methods for predicting the probability of cardiac allograft rejection via profiling of peripheral blood gene expression are also provided.
1. A method for identifying cardiac transplant tissue rejection in a human subject, said method comprising:
determining a first gene expression profile in a blood sample taken from said human subject, wherein said first gene expression profile comprises the nucleic acid expression level of the ubiquinol-cytochrome c reductase binding protein (UQCRB) gene; and
comparing said first gene expression profile to a second gene expression profile, wherein said second gene expression profile comprises the nucleic acid expression level of the UQCRB gene derived from blood samples collected from a human cardiac transplant population that does not have cardiac transplant tissue rejection,
wherein a statistically significant increase in UQCRB gene expression in said first gene expression profile compared to said second gene expression profile is indicative of cardiac transplant tissue rejection in said human subject.
2. The method of claim 1 , wherein said first and second gene expression profiles further comprise the nucleic acid expression level of the basic transcription factor 3 (BTF3) gene, the suppression of tumorigenicity 13 (ST13) gene, and the cullin 4A (CUL4A) gene.
3. The method of claim 2 , wherein a statistically significant increase in BTF3, ST13, or CUL4 gene expression in said first gene expression profile compared to said second gene expression profile is indicative of cardiac transplant tissue rejection in said human subject.
4. The method of claim 1 , wherein said first and second gene expression profiles further comprise the nucleic acid expression level of the CASP8 and FADD-like apoptosis regulator (CFLAR) gene.
5. The method of claim 4 , wherein a statistically significant decrease in CFLAR gene expression in said first gene expression profile compared to said second gene expression profile is indicative of cardiac transplant tissue rejection in said human subject.
6. The method of claim 1 , wherein said first and second gene expression profiles comprise the nucleic acid expression level of a plurality of expressed sequence tags (ESTs).
7. The method of claim 6 , wherein at least one of said expressed sequence tags comprises a nucleic acid comprising SEQ ID NO: 12.
8. The method of claim 1 , wherein the identified caridac transplant tissue rejection is a cardiac allograft.
9. The method of claim 1 , wherein said determining a first gene expression profile is conducted by the use of a microarray.